Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13641068 | 0.92 | CCR3 (0.41) | OPRM1OPRL1OPRK1KCNH2DRD2 | |
| SCHEMBL13640792 | 0.87 | POLB (0.37) | OPRM1OPRL1KCNH2DRD2SMN1; SMN2 | |
| SCHEMBL13640808 | 0.80 | OPRM1 (0.54) | OPRM1OPRL1OPRD1OPRK1DRD2 | |
| SCHEMBL12293656 | 0.80 | OPRM1 (0.54) | OPRM1OPRL1OPRD1OPRK1DRD2 | |
| SCHEMBL12084552 | 0.80 | CHRM1 (0.47) | OPRM1OPRL1OPRD1OPRK1KCNH2 | |
| SCHEMBL13643898 | 0.79 | KCNH2 (0.40) | OPRM1OPRL1OPRD1OPRK1KCNH2 | |
| SCHEMBL13640785 | 0.79 | SETD2 (0.38) | OPRM1OPRL1DRD2CHRM1MEN1 | |
| SCHEMBL13641006 | 0.79 | POLB (0.44) | DRD2CHRM1SMN1; SMN2 | |
| SCHEMBL23798578 | 0.78 | CHRM1 (0.40) | OPRM1OPRL1KCNH2CHRM1 | |
| SCHEMBL12928876 | 0.77 | KCNH2 (0.40) | OPRM1OPRL1OPRD1OPRK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | OPRM1 177/4885OPRL1 108/4885OPRD1 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.